How Global Investors Structure, Finance & Acquire Australian Biotech

Biotech is no longer a fringe asset class it’s a frontier of global capital deployment, strategic acquisitions, and highmgrowth innovation Biotech is no longer a fringe asset class it’s a frontier of global capital deployment, strategic acquisitions, and high-growth innovation. But investing in biotech isn’t just about believing in a breakthrough it’s about structuring deals correctly, managing cross border capital flows, and avoiding the pitfalls that destroy value. If you're a family office, institutional investor, wealth manager, strategic buyer, or sophisticated individual investor considering biotech opportunities especially in the Asia Pacific this session is for you. This exclusive briefing brings together deal practitioners with deep operational exposure in structuring, financing, and acquiring biotech assets including those with real, in flight deals today.